Sticking Together to Thwart Cancer

English

Prof. Benjamin Geiger

The cells in our tissues and organs are generally good neighbors. They speak to one another regularly, stay in one home for life, heed their environment and even limit their offspring to prevent overcrowding.


Sometimes, however, a "bully" cell is born or moves into the area, where it ignores other inhabitants and its surroundings, moves around and reproduces uncaringly. That "bully" is a tumor cell, and it can ruin the neighborhood.

Profs. Benjamin Geiger and Avri Ben-Ze'ev of the Molecular Cell Biology Department are studying how cells manage to maintain good neighborliness through communication and how this process goes awry in tumor cells.

Cell communication takes place when cells adhere to their surrounding substance, the matrix, and to their neighboring cells. This adhesion anchors cells in one place and enables them to link up to form tissues and organs and to exchange signals that control their behavior. Molecules known as junctional proteins, found in and just under the cell membrane, join cells with the matrix and with their neighbors, and carry adhesion signals to the cell interior.

Tumor cells are known to be associated with poor adhesiveness, and Geiger and Ben-Ze'ev believe this contributes to cancer in two ways. First, while normal cells receive signals to stop reproducing when they reach a certain density, the lack of adhesion to the matrix and to other cells that is characteristic of tumor cells means these cells do not receive such signals.

"Normal cells don't like overcrowding," says Geiger. "Once cell density reaches a certain optimal level in a normal tissue or organ, specific signals induce growth arrest. Tumor cells usually don't respond to crowding in this way; they keep reproducing, one on top of the other."

Second, the reduced adhesion of cells within a tumor means they are freer to migrate and spread, or metastasize, leading to secondary cancers.

The Institute scientists have made several discoveries that throw light on adhesion-related cell signaling and its connection with cancer. Two decades ago, Geiger identified the first junctional protein, vinculin. Around the same time, Ben-Ze'ev demonstrated that adhesion to the right matrix is essential for normal cell functioning, and that cells denied this adhesion show marked changes in gene expression, the process by which a particular gene produces its protein. Uncontrolled growth, the hallmark of cancer, can proceed in the absence of adhesion.

More recently, Ben-Ze'ev and Geiger found that in tumor cells some junctional proteins, such as vinculin, actinin and plakoglobin, are present in reduced amounts or are absent altogether. When they genetically manipulated human kidney cancer cells to contain these proteins, tumor growth was inhibited.

"This suggests that a reduction in junctional proteins is probably an essential step for tumor formation," says Ben-Ze'ev.

This research also produced an unexpected finding. In their engineered tumor cells, Ben-Ze'ev and Geiger noticed that plakoglobin was not located in its usual place under the membrane, but had made its way to the cell nucleus and was apparently suppressing tumor growth from there. This led to their realization that in normal cells plakoglobin is present also in the nucleus, albeit in minute amounts, as well as under the membrane. The scientists suggest that this "dual nationality" for a molecule such as plakoglobin might be a previously unknown means to control cell growth -- the molecule not only affects cell adhesion and signaling from its usual place under the membrane but probably also acts on genes involved in regulating cell growth, affecting their expression. While the mechanism by which the protein enters the nucleus, and exactly what it does there, are still under study, this finding may shed further light on the development of tumor cells.

The scientists also believe that their research has the potential for helping in the design of a future cancer therapy that would aim to halt tumor growth by improving cellular adhesion and communication.
Life Sciences
English

Cellular "Suicide Weapon" Discovered

English
An enzyme that acts as the "weapon" with which cells "commit suicide" has been discovered by an Institute team led by Prof. David Wallach of the Membrane Research and Biophysics Department. The finding may lead to treatments for autoimmune disorders caused by abnormal cellular self-destruction, such as juvenile diabetes or multiple sclerosis.

"We've identified a crucial step in the self-annihilation of cells and may now be able to control this process," Wallach says.

All cells have a normal ability to "commit suicide" when they become redundant, but in certain diseases the immune system erroneously commands healthy cells to do so. In these disorders, a cell receives the suicide message through receptor molecules known as Fas/Apo-1 and through tumor necrosis factor receptors.

Wallach's team has now discovered the "weapon" that translates this message into action: an enzyme they call MACH. This enzyme cuts up vital proteins inside a cell, disrupting the cell's normal functions and killing it. The team has also found that the suicide message is transmitted with surprising directness. Unlike many other cellular processes that involve multiple stages, this one goes directly from the receptor to the enzyme.

The new understanding may make it possible to block the suicide mechanism when it causes disease.
Life Sciences
English

Mysteries of Embryo Development Probed

English

Profs. Geiger and Kam. A new view of embryonic development

 

Institute researchers have thrown new light on one of the greatest mysteries of biology - how intricate cellular mechanisms allow the fertilized egg, a single cell, to develop into a complex three-dimensional structure with trillions of cells that form various tissues and organs.


Genetically controlled mechanisms underlying the formation of organs in a developing embryo are studied by Profs. Benjamin Geiger and Zvi Kam of the Department of Chemical Immunology in collaboration with Dr. Anat Yarden and Sigal Bitzur. Their research model is the zebrafish, whose nearly transparent embryos complete crucial developmental steps in less than a day. The scientists focus on several families of genes, particularly those leading to the production of adhesion molecules involved in the assembly of individual cells into tissues and organs.

In order to observe organ formation in a live embryo, the researchers have designed a novel microscopic system that follows the development and movement of embryonic cells. The complex data are processed in a powerful computer, producing a digital multidimensional image. The result is a time-lapse recording that captures the 20 hours during which a fertilized egg develops into a partially formed embryo with tens of thousands of cells.

In applying this new approach to the study of cell adhesion molecules, the scientists have shown that these proteins, present on the surfaces of cells, serve a dual function. While long known to hold cells together, recent Weizmann results indicate that they also help to recruit signal transduction molecules that trigger processes such as cell growth and differentiation. The adhesion sites thus serve as miniature "communication centers" affecting cell behavior and fate.

A disruption of these complex mechanisms in either embryos or mature organisms can lead to disease. For example, the mechanism of contact inhibition, which instructs cells to stop growing when they reach a certain density in tissues, is lost in cancer cells. Consequently, an understanding of the way contact signals are transmitted into cells may eventually aid researchers to develop effective new means of suppressing tumor growth.

Prof. Geiger holds the Erwin Neter Chair of Tumor Biology and Prof. Kam, the Israel Pollak Chair of Biophysics.
 
Development in a day
 
 
Life Sciences
English

High-Level Biosafety Laboratory Established

English

Front-lines in the battle against disease

 

More detailed research on potentially dangerous microorganisms will now be possible at the Institute thanks to the new Marcel Mérieux Foundation Biohazard-P3 Laboratory, established last month on the Weizmann campus. The environmentally isolated facility will enable a major scaling-up of biomedical studies in various important fields.


Among the microorganisms already being studied at the Institute are disease-inducing viruses such as hepatitis B; bacteria such as pertussis and shigella; and parasites such as leishmania and amoeba. By providing safe containment of these organisms and of the infectious nucleic acids, plasmids and recombinant DNA introduced into them, the new laboratory enables the study of far greater quantities of these disease-inducing vectors, as well as more pathogenic varieties. In addition, it makes it possible to conduct new avenues of AIDS-related research at the Institute, including direct investigation of the HIV virus and of blood from people with AIDS.

The sophisticated engineering features of the facility include specialized ventilation systems, a controlled access zone separating the laboratory from areas open to the public, disinfectant showers and a fumigation system.

The new P3 laboratory is headed by Prof. Gideon Berke of the Department of Cell Biology, who has been in charge of the Institute's Safety Services Unit for the past decade. "The Institute," says Berke, "has always given top priority to the safety of both our own personnel and the community at large, and the establishment of the facility is a reflection of this policy. Moreover, it enables Institute researchers to engage in every type of research on the front line of the battle against infectious disease. Hospitals and biomedical companies have already expressed an interest in utilizing the P3 laboratory for new collaborative projects with the Institute."

The Biohazard-P3 Laboratory was provided to the Institute by the Marcel Mérieux Foundation in Lyon, France. Its creator, the late Marcel Mérieux, an associate of Louis Pasteur, was a producer of vaccines and blood products for human and veterinary medicine. Formerly directed by Dr. Charles Mérieux, Marcel's son and the founder of the Pasteur-Mérieux-Weizmann Committee in Lyon, the Foundation is now under the directorship of Marcel's grandson Alain.

Prof. Berke holds the Isaac and Elsa Bourla Chair of Cancer Research.
 
Life Sciences
English

Pages